TAKEDA-143242 increased survival via reduced cytokines in porcine peritonitis

Journal of Surgical Research

Volumn 166, Issue 2, 2011, Pages

  Goldfarb, Roy D ^a,b   Ortegel, John W ^a   Parrillo, Joseph E ^a   Zanotti Cavazzoni, Sergio ^a   Casey, Larry C ^a   Dellinger, R Phillip ^a  

^a RUSH MEDICAL COLLEGE   (United States)

^b Department of Anesthesiology   (United States)

Author keywords

blind study; cardiac function, peritonitis; IL 1 ; IL 6; pulmonary vascular resistance; TAK 242; TNF ; toll like receptor 4 (TLR 4)

Indexed keywords

CYTOKINE; FIBRIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; RESATORVID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ESCHERICHIA COLI INFECTION; GRAM NEGATIVE SEPSIS; LD 50; LUNG ARTERY PRESSURE; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION;

EID: 79952485787     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2010.09.031     Document Type: Article

References (26)

1. A.P. Wheeler, and G.R. Bernard Treating patients with severe sepsis N Engl J Med 340 1999 207
2. D.C. Angus, W.T. Linde-Zwirble, and J. Lidicker Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care Crit Care Med 29 2001 1303
3. S.L. Zanotti-Cavazzoni, and R.D. Goldfarb Animal models of sepsis Crit Care Clin 25 2009 703
4. R.D. Goldfarb, D. Glock, and A. Kumar A porcine model of peritonitis and bacteremia simulates human septic shock Shock 6 1996 442
5. M.M. Swindle, A.C. Smith, and B.J. Hepburn Swine as models in experimental surgery J Invest Surg 1 1988 65
6. T. van der Poll, and S.M. Opal Host-pathogen interactions in sepsis Lancet Infect Dis 8 2008 32
7. Goldfarb R, Ghandi S, Cinel I, et al. In: Fifth NIH Symposium on Critical Illness (2007).
8. H. Kumar, T. Kawai, and S. Akira Toll-like receptors and innate immunity Biochem Biophys Res Commun 388 2009 621
9. O. Takeuchi, K. Hoshino, and T. Kawai Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components Immunity 11 1999 443
10. J. Cohen The immunopathogenesis of sepsis Nature 420 2002 885
11. L.C. Casey, R.A. Balk, and R.C. Bone Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome Ann Intern Med 119 1993 771
12. L.D. Butler, N.K. Layman, and R.L. Cain Interleukin 1-induced pathophysiology: Induction of cytokines, development of histopathologic changes, and immunopharmacologic intervention Clin Immunol Immunopathol 53 1989 400
13. A.T. Silva, K.F. Bayston, and J. Cohen Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-α in experimental gram-negative shock J Infect Dis 162 1990 421
14. M. Ii, N. Matsunaga, and K. Hazeki A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling Mol Pharmacol 69 2006 1288
15. M. Yamada, T. Ichikawa, and M. Ii Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: Synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex- 1-ene-1-carboxylate J Med Chem 48 2005 7457
16. T. Sha, M. Sunamoto, and T. Kitazaki Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model Eur J Pharmacol 571 2007 231
17. T. Kawamoto, M. Ii, and T. Kitazaki TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain Eur J Pharmacol 584 2008 40
18. R.D. Goldfarb, T.S. Parker, and D.M. Levine Protein-free phospholipid emulsion treatment improved cardiopulmonary function and survival in porcine sepsis Am J Physiol Regul Integr Comp Physiol 284 2003 R550
19. R.D. Goldfarb, D. Glock, and K. Johnson Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock Shock 10 1998 258
20. K. Sagawa The ventricular pressure-volume diagram revisited Circ Res 43 1978 677
21. A. Lenz, G.A. Franklin, and W.G. Cheadle Systemic inflammation after trauma Injury 38 2007 1336
22. E. Jean-Baptiste Cellular mechanisms in sepsis J Intensive Care Med 22 2007 63
23. M. Yamada, T. Ichikawa, and T. Yamano Optically active cyclohexene derivative as a new antisepsis agent: An efficient synthesis of ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242) Chem Pharm Bull (Tokyo) 54 2006 58
24. J. Szebeni, J.L. Fontana, and N.M. Wassef Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: A model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody Circulation 99 1999 2302
25. Matsunaga N, Tsuchimori N, Matsumoto T, Ii M. TAK-242 (Resatorvid), a Small Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules. Mol Pharmacol 2010 Sep 29. [Epub ahead of print].
26. T.W. Rice, A.P. Wheeler, and G.R. Bernard A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis Crit Care Med 38 2010 1685